biostudies-literatureUnknown162(1)Miglio G<h4>Background and purpose</h4>Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors, and three subtypes (α, β and γ) have been identified. PPAR activation has been reported to decrease renal injury and markers of glomerular dysfunction in models of renal ischemia/reperfusion (I/R). However, both the I/R effects and the effects of PPAR agonists on podocytes, an integral cellular part of the glomerular filtration barrier, remain to be established.<h4>Experimental approach</h4>By using oxygen/glucose deprivation-reoxygenation as an in vitro model that mimics in vivo I/R, the effects of PPAR agonists on podocyte death were compared. Human immortalized podocytes were treated with gemfibrozil, GW0742, pioglitazone or rosiglitazone, as a single or repeateBritish journal of pharmacology111-25https://www.ebi.ac.uk/biostudies/studies/S-EPMC3012410biostudies-literatureThe subtypes of peroxisome proliferator-activated receptors expressed by human podocytes and their role in decreasing podocyte injury.PMC3012410Miglio GRattazzi LGrange CCollino MCamussi GFantozzi RRosa ACfalseThe subtypes of peroxisome proliferator-activated receptors expressed by human podocytes and their role in decreasing podocyte injury.<h4>Background and purpose</h4>Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors, and three subtypes (α, β and γ) have been identified. PPAR activation has been reported to decrease renal injury and markers of glomerular dysfunction in models of renal ischemia/reperfusion (I/R). However, both the I/R effects and the effects of PPAR agonists on podocytes, an integral cellular part of the glomerular filtration barrier, remain to be established.<h4>Experimental approach</h4>By using oxygen/glucose deprivation-reoxygenation as an in vitro model that mimics in vivo I/R, the effects of PPAR agonists on podocyte death were compared. Human immortalized podocytes were treated with gemfibrozil, GW0742, pioglitazone or rosiglitazone, as a single or repeate2011-01-01T00:00:00Z2011 Jan2025-04-20T03:57:38.201Z2019-03-27T00:37:44ZS-EPMC30124102084047010.1111/j.1476-5381.2010.01032.x